Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Assessment of the Type I IFN Response in the Nasal Cavity During Respiratory Viral Infections in a Geriatric Department (RESPIGERIA)

15 maja 2026 zaktualizowane przez: Hospices Civils de Lyon

The diagnosis of respiratory viral infections is usually based on testing for pathogens suspected of causing the infection using PCR tests that target the pathogens' DNA or RNA. A specific PCR test is required for each pathogen. In most cases, testing is carried out primarily for three specific viruses (SARS-CoV-2, respiratory syncytial virus (RSV), influenza virus) is carried out as a first-line test. However, numerous viruses can cause these infections (adenovirus, metapneumovirus, rhinovirus, parainfluenza virus, bocavirus, etc.). Consequently, performing a specific PCR test for every virus that could cause respiratory symptoms is not feasible, and viral infections are often under-diagnosed because the screening for viruses is not exhaustive.

To address this issue, analysing the host response to determine the microbial aetiology of an infection may represent an innovative alternative for the diagnosis of infections. A common feature of all viruses is their ability to induce type I interferons (IFN-I). Thus, measuring this IFN-I response could help direct the diagnosis of respiratory infections towards a viral origin.

Furthermore, the detection of a virus via PCR in a respiratory sample may indicate an active or recent infection, but may also be detected following an infection that occurred several weeks or months earlier. The viral load in the sample is an important factor in distinguishing between these two scenarios but does not always allow for a definitive conclusion (some patients may have low viral loads whilst still having an active infection). It is therefore sometimes difficult to distinguish, using a PCR test that detects the viral genome, between the virus currently replicating and traces of viral genetic material from dead viruses. It is therefore necessary to have markers that can be associated with an active/replicating infection to aid interpretation in the event of a positive PCR result.

Using nasopharyngeal swabs collected for the diagnosis of SARS-CoV-2 infection, we were able to demonstrate that it is possible to measure the IFN-I response. These proteins, which possess antiviral properties, are secreted by immune cells during infection to limit viral replication.

Thus, the combination of simultaneous testing for the pathogen and the IFN response has made it possible to link the replicative nature of the SARS-CoV-2 virus with IFN-I production.

Our latest research into SARS-CoV-2 has thus led to the identification of a marker of the IFN-I response associated with active viral replication, which we have confirmed using viral culture techniques that detect only live/infectious virus.

However, the IFN-I response may be compromised in older and very old individuals, particularly due to certain comorbidities or treatments, the prevalence of which increases with age.

The aim of this study is to assess the IFN-I response in the context of respiratory infections caused by various viruses, in a population admitted to a geriatric ward and a population from the REFIPA protocol (NCT07239830), a study designed to establish reference values for nasal and blood interferon scores in uninfected elderly subjects.

There is a need to improve the diagnosis of viral infections, particularly in geriatric wards where the burden of viral infections is very significant for patients, carers and the organisation of care. Rapid diagnosis of viral infections would enable the optimisation of isolation measures and hygiene protocols within these wards. Furthermore, it is important to validate new markers that could aid in the interpretation of a positive PCR result for respiratory viruses. Some PCR tests can indeed remain positive for several weeks or even months due to the detection of traces of viral genetic material.

Thus, new markers indicating an active or recent infection could be useful in facilitating interpretation, alongside other clinical and/or virological findings.

The aim is, by combining different results, to improve the diagnosis of viral infections and to avoid over-diagnosing respiratory viral infections due to a positive PCR result that may in fact correspond to a past infection.

Przegląd badań

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

1140

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

      • Lyon, Francja, 69310
        • Rekrutacyjny
        • Hôpital Lyon Sud

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

This study focuses on nasopharyngeal swabs taken as part of clinical care to screen for respiratory viruses in patients admitted to geriatric wards, or as part of the REFIPA protocol (NCT07239830) in older, asymptomatic, non-hospitalised participants. For hospitalised patients, first-line microbiological tests (RSV, SARS-CoV-2 and influenza) as well as viral culture are carried out as part of routine diagnostic testing. For participants in the REFIPA protocol (NCT07239830), samples were collected as part of this study.

Thus, all samples are collected as part of standard care in hospitalised patients in geriatric wards presenting with signs of respiratory distress, or as part of the REFIPA protocol in asymptomatic, non-hospitalised elderly participants.

The IFN-I score and the results of second-line tests will not be disclosed to the patient's doctor. They will therefore have no impact on the patient's treatment.

Opis

Inclusion Criteria:

  • Patients admitted to a geriatric ward or participants diagnosed with a PCR-positive infection based on a swab sample taken as part of the REFIPA study (NCT07239830). Nasopharyngeal swab taken for viral detection, where the viral test was carried out as part of standard clinical care (minimum 500 µL required)

Exclusion Criteria:

  • The patient's objection to the use of their data in this study

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Respiratory viral infection geriatric patients

Nasopharyngeal swabs taken from patients admitted to geriatric wards with suspected respiratory viral infection will be selected by the Regional Biological Reference Centres (CRBs). As part of clinical care, the detection of a respiratory virus relies on a first-line diagnostic test. The IFN-I response can be analysed using these same samples, without the need for additional collection.

Furthermore, the ability of the IFN-I response to detect replicating viruses can be tested using viral culture results.

The IFN-I score will be determined from samples tested for the viruses targeted in the first-line testing (influenza, SARS-CoV-2 and RSV) or from samples tested as part of the REFIPA protocol (NCT07239830). A positive score is defined as a threshold > 2.47.

The diagnosis of respiratory viral infection will be established based on a positive result from at least one of the three first-line PCR tests for viruses performed on nasopharyngeal swabs, considered as reference tests or as part of the REFIPA study (NCT07239830).

Respiratory viral infection geriatric patients from REFIPA study (NCT07239830)
Participants who were withdrawn from the REFIPA study (NCT07239830) following a diagnosis of infection based on a positive PCR result from a swab taken as part of the study

The IFN-I score will be determined from samples tested for the viruses targeted in the first-line testing (influenza, SARS-CoV-2 and RSV) or from samples tested as part of the REFIPA protocol (NCT07239830). A positive score is defined as a threshold > 2.47.

The diagnosis of respiratory viral infection will be established based on a positive result from at least one of the three first-line PCR tests for viruses performed on nasopharyngeal swabs, considered as reference tests or as part of the REFIPA study (NCT07239830).

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Evaluate the diagnostic performance of the IFN-I score for detecting respiratory viral infection vs first-line tests (influenza, SARS-CoV-2, RSV) in geriatric patients or REFIPA (NCT07239830) participants withdrawn due to PCR-confirmed infection on study
Ramy czasowe: One time

The IFN-I score will be determined from samples tested for the viruses targeted in the first-line testing (influenza, SARS-CoV-2 and RSV) or from samples tested as part of the REFIPA protocol (NCT07239830). A positive score is defined as a threshold > 2.47.

The diagnosis of respiratory viral infection will be established based on a positive result from at least one of the three first-line PCR tests for viruses performed on nasopharyngeal swabs, considered as reference tests or as part of the REFIPA study (NCT07239830).

One time

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

4 stycznia 2024

Zakończenie podstawowe (Szacowany)

31 maja 2026

Ukończenie studiów (Szacowany)

31 lipca 2027

Daty rejestracji na studia

Pierwszy przesłany

15 maja 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

15 maja 2026

Pierwszy wysłany (Rzeczywisty)

22 maja 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

22 maja 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

15 maja 2026

Ostatnia weryfikacja

1 maja 2026

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Infekcja wirusowa dróg oddechowych

Subskrybuj